REQUEST A DEMO
Total
USD $0.00
Search more companies

Sk Bio Science Co.,Ltd. (South Korea)

Main Activities: Pharmaceutical Preparation Manufacturing
Full name: Sk Bio Science Co.,Ltd. Profile Updated: July 08, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

The Company is a Korea-based company mainly engaged in the manufacture and sale of biological products. The Company s main products include vaccines such as SKYCellflu and Rotatech. The Company also sells infusion solutions. In addition, the Company engages in technology export business. The Company sells its products in domestic and overseas markets. The Company was founded on July 1, 2018 and its shares are listed on Korea Stock Exchange on March 18, 2021.

Headquarters
310, Pangyo-Ro, Bundang-Gu
Seongnam; Gyeonggi;

Contact Details: Purchase the Sk Bio Science Co.,Ltd. report to view the information.

Website: http://www.skbioscience.co.kr

Basic Information
Total Employees:
Purchase the Sk Bio Science Co.,Ltd. report to view the information.
Outstanding Shares:
Purchase the Sk Bio Science Co.,Ltd. report to view the information.
Registered Capital:
Purchase the Sk Bio Science Co.,Ltd. report to view the information.
Financial Auditors:
Purchase the Sk Bio Science Co.,Ltd. report to view the information.
Incorporation Date:
July 01, 2018
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Purchase this report to view the information.
Chief Technology Officer
Purchase this report to view the information.
Outside Director
Purchase this report to view the information.
Outside Director
Purchase this report to view the information.
Outside Director
Subsidiaries
에스케이바이오사이언스(주)
Company Performance
Financial values in the chart are available after Sk Bio Science Co.,Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
4.19%
Total operating revenue
6.26%
Operating profit (EBIT)
26.37%
EBITDA
39.69%
Net Profit (Loss) for the Period
16.92%
Total assets
-0.11%
Total equity
1.54%
Operating Profit Margin (ROS)
41.65%
Net Profit Margin
13.02%
Return on Equity (ROE)
0.32%
Debt to Equity Ratio
4.18%
Quick Ratio
3.62%
Cash Ratio
1.13%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?